Physician profile
David M Pierce
NPI 1316062722
$1,248.93
in general payments reported to CMS, 2019-2025
12 companies · $79.48 in 2025
The $79.48 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $115 · 2021: $146 · 2022: $212 · 2023: $231 · 2024: $172 · 2025: $79.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $286.74 | 2019-2022 | |
| Abb Con-Cise Optical Group LLC | $250.58 | 2020-2024 | Contact Lens, Spectacle Lenses |
| Shire North American Group INC | $140.58 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $124.99 | 2023 | Star S4 Ir |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $102.25 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $83.01 | 2022-2025 | Infuse |
| Coopervision INC. | $79.55 | 2019-2024 | Clariti Contact Lens, Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $46.33 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $43.90 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $34.65 | 2024 | Xdemvy |
| Oyster Point Pharma, INC. | $31.74 | 2025 | Tyrvaya |
| Biotissue Holdings INC. | $24.61 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.